EVIDENCE CHECK · UPDATED 17 AUGUST 2026
Exenatide for cats: what do veterinary studies show?
Controlled studies in cats have tested exenatide for diabetes-related outcomes and obesity. Results are mixed, study groups are small, and the evidence does not establish a consumer weight-loss treatment for cats.
What the controlled studies found
A 2025 study in 22 cats found no difference in diabetic-remission duration between monthly exenatide extended-release and placebo, although hemoglobin A1c differed. A 2016 pilot in 30 newly diagnosed diabetic cats reported numerically higher remission and metabolic-control rates with exenatide, but those group differences were not statistically significant.
What remains uncertain
The studies do not establish which cats, if any, receive a meaningful clinical benefit beyond standard diabetes management. Larger trials are needed, and PeptiVet Labs does not provide a dosing recommendation.
What the obesity study showed
In a 12-cat placebo-controlled obesity study, exenatide did not significantly change insulin, glucose tolerance, body composition or body weight compared with placebo. Two treated cats had mild self-limiting gastrointestinal signs and one had mild hypoglycemia.
What cat owners should do
Do not use a human GLP-1 prescription or an online peptide product in a cat. Diabetes and weight management require veterinary diagnosis, monitoring and a jurisdiction-appropriate treatment plan.